Eplerenone: A selective aldosterone receptor antagonist for patients with heart failure

被引:19
作者
Barnes, BJ
Howard, PA
机构
[1] Univ Kansas, Med Ctr, Dept Pharm Practice, Kansas City, KS 66160 USA
[2] Univ Kansas, Med Ctr, Dept Cardiothorac Surg, Kansas City, KS 66160 USA
关键词
aldosterone receptor antagonist; eplerenone; heart failure; left-ventricular dysfunction;
D O I
10.1345/aph.1E306
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To evaluate the pharmacology, pharmacokinetics, safety, and clinical use of eplerenone in heart failure (HF). Data Sources: English-language MEDLINE searches were performed from 1966 to May 2004. Key words included eplerenone, aldosterone receptor antagonist, heart failure, myocardial infarction, left-ventricular dysfunction, and cost-effectiveness. Additional references were identified from bibliographies of selected articles. Study Selection and Data Extraction: Human trials evaluating the efficacy, safety, and cost-effectiveness of aldosterone receptor antagonists in HF were evaluated. Data Synthesis: Eplerenone is the first selective aldosterone receptor antagonist. The drug is indicated to improve the survival of stable patients with left-ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of HF following acute myocardial infarction. Efficacy and safety in this population have been demonstrated in a large, randomized clinical trial. Eplerenone is associated with severe and sometimes life-threatening hyperkalemia. Patients with reduced renal function and diabetes, as well as those on other drugs that increase potassium levels, are at highest risk. Eplerenone is metabolized by the cytochrome P450 system and may interact with drugs that interfere with this system. A major advantage of eplerenone over the nonselective aldosterone receptor antagonist spironolactone is lack of binding to progesterone and androgen receptors, which is associated with drug-induced gynecomastia, breast pain, and impotence. Conclusions: The addition of eplerenone to traditional HF therapy has been shown to reduce morbidity and mortality in patients who develop left-ventricular dysfunction after acute myocardial infarction. Eplerenone's selectivity reduces sex hormone-related adverse effects. Despite these benefits, the overall cost-effectiveness has yet to be determined.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 42 条
[1]  
ABSHAGEN U, 1976, N-S ARCH PHARMACOL, V296, P37, DOI 10.1007/BF00498838
[2]  
Adams KF, 1999, J CARD FAIL, V5, P357
[3]  
*AM HEART ASS, 2003, HEART DIS STROK STAT
[4]   Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production [J].
Brown, NJ ;
Kim, KS ;
Chen, YQ ;
Blevins, LS ;
Nadeau, JH ;
Meranze, SG ;
Vaughan, DE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :336-344
[5]   Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure [J].
Cicoira, M ;
Zanolla, L ;
Rossi, A ;
Golia, G ;
Franceschini, L ;
Brighetti, G ;
Marino, P ;
Zardini, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :304-310
[6]  
COHEN HE, 2004, DRUG TOPICS RED BOOK
[7]  
DAVIS B, HARP TRIAL INFORMATI
[8]  
DEGASPARO M, 1987, J PHARMACOL EXP THER, V240, P650
[9]   Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology [J].
Delyani, JA .
KIDNEY INTERNATIONAL, 2000, 57 (04) :1408-1411
[10]  
DORMARUNNO K, 2004, EPLERENONE POST ACUT